$112.71
Lantheus is a drug manufacturers - specialty & generic business based in the US. Lantheus shares (LNTH) are listed on the NASDAQ and all prices are listed in US Dollars. Lantheus employs 834 staff and has a trailing 12-month revenue of around $1.4 billion.
Our top picks for where to buy Lantheus stock
How to buy Lantheus stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – LNTH. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Lantheus stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Lantheus stock price (NASDAQ: LNTH)
Use our graph to track the performance of LNTH stocks over time.Lantheus shares at a glance
Latest market close | $112.95 |
---|---|
52-week range | $50.20 - $126.89 |
50-day moving average | $86.07 |
200-day moving average | $69.17 |
Wall St. target price | $136.40 |
PE ratio | 17.8034 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $6.56 |
Is it a good time to buy Lantheus stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Lantheus price performance over time
Historical closes compared with the close of $112.95 from 2024-07-25
1 week (2024-07-19) | -3.29% |
---|---|
1 month (2024-06-26) | 43.85% |
3 months (2024-04-26) | 72.28% |
6 months (2024-01-26) | 113.60% |
1 year (2023-07-26) | 34.35% |
---|---|
2 years (2022-07-22) | N/A |
3 years (2021-07-26) | 340.01% |
5 years (2019-07-26) | 396.05% |
Is Lantheus stock undervalued or overvalued?
Valuing Lantheus stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Lantheus's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Lantheus's P/E ratio
Lantheus's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, Lantheus shares trade at around 18x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Lantheus's PEG ratio
Lantheus's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.61. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Lantheus's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Lantheus's EBITDA
Lantheus's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $544.5 million.
The EBITDA is a measure of a Lantheus's overall financial performance and is widely used to measure a its profitability.
Lantheus financials
Revenue TTM | $1.4 billion |
---|---|
Operating margin TTM | 27.13% |
Gross profit TTM | $581.7 million |
Return on assets TTM | 19.01% |
Return on equity TTM | 66.21% |
Profit margin | 33.72% |
Book value | $13.65 |
Market Capitalization | $8.1 billion |
TTM: trailing 12 months
Lantheus share dividends
We're not expecting Lantheus to pay a dividend over the next 12 months.
Lantheus share price volatility
Over the last 12 months, Lantheus's shares have ranged in value from as little as $50.2 up to $126.8899. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lantheus's is 0.515. This would suggest that Lantheus's shares are less volatile than average (for this exchange).
Lantheus overview
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc. ; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC.
Frequently asked questions
What percentage of Lantheus is owned by insiders or institutions?Currently 2.578% of Lantheus shares are held by insiders and 100.15% by institutions. How many people work for Lantheus?
Latest data suggests 834 work at Lantheus. When does the fiscal year end for Lantheus?
Lantheus's fiscal year ends in December. Where is Lantheus based?
Lantheus's address is: 201 Burlington Road, Bedford, MA, United States, 01730 What is Lantheus's ISIN number?
Lantheus's international securities identification number is: US5165441032 What is Lantheus's CUSIP number?
Lantheus's Committee on Uniform Securities Identification Procedures number is: 516544103
More guides on Finder
-
Opto review 2024: $0 commission, fractional theme investing
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
-
Best paper trading platforms to practice trading with fake money [2024]
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
-
How to buy the new spot Ethereum ETFs
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
-
Best broker cash sweep rates for July 2024
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
7 best day trading platforms of July 2024
These are the best day trading platforms, according to Finder’s comprehensive analysis.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 top semiconductor stocks to buy in 2024
We’ve rounded up stats on some of the most popular semiconductor stocks, along with information on how they compare and how to invest.
-
11 best brokerage accounts of July 2024: Top picks for investors
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
7 best ways to invest $10K
Check out our 7 ideas for how to invest $10K to maximize your money.
Ask a question